Melanie Schorr1,2, Dean A Marengi1, Reitumetse L Pulumo1, Elaine Yu2,3, Kamryn T Eddy2,4, Anne Klibanski1,2, Karen K Miller1,2, Elizabeth A Lawson1,2. 1. Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114. 2. Harvard Medical School, Boston, Massachusetts 02115. 3. Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114. 4. Eating Disorders Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts 02114.
Abstract
Context: Oxytocin (OXT), an anorexigenic hypothalamic hormone anabolic to bone, may reflect energy availability. Basal serum OXT levels are lower in anorexia nervosa (AN, state of energy deficit) than healthy controls (HC) and negatively associated with spine bone mineral density (BMD). Reports are conflicting regarding OXT levels in overweight/obesity (OB, state of energy excess). Relationships between OXT and BMD in OB and hip geometry across the weight spectrum are unknown. Objective: To determine whether overnight serum OXT levels are (1) elevated in OB and (2) associated with body composition, BMD, and hip geometry across the weight spectrum. Design: Cross-sectional. Setting: Clinical research center. Participants: Fifty-nine women, ages 18 to 45 years: amenorrheic AN (N = 16), eumenorrheic HC (N = 24), eumenorrheic OB (N = 19). Main Outcome Measures: Serum sampled every 20 minutes from 8 pm to 8 am and pooled for integrated overnight OXT levels. Body composition, BMD, and hip structural analysis measured by dual x-ray absorptiometry. Results: OXT levels were lowest in AN, higher in HC, and highest in OB (P ≤ 0.02). There were positive associations between OXT and (1) body mass index (P = 0.0004); (2) total, visceral, and subcutaneous fat (P ≤ 0.0002); (3) spine and hip BMD Z-scores (P ≤ 0.01); and (4) favorable hip geometry, namely buckling ratio (P ≤ 0.05). In a subset analysis of HC and OB, relationships between OXT and body composition, but not bone parameters, remained significant. Conclusions: These data suggest OXT is a marker of energy availability and may be a mediator of bone density, structure, and strength. OXT pathways may provide targets for obesity and osteoporosis treatment.
Context:Oxytocin (OXT), an anorexigenic hypothalamic hormone anabolic to bone, may reflect energy availability. Basal serum OXT levels are lower in anorexia nervosa (AN, state of energy deficit) than healthy controls (HC) and negatively associated with spine bone mineral density (BMD). Reports are conflicting regarding OXT levels in overweight/obesity (OB, state of energy excess). Relationships between OXT and BMD in OB and hip geometry across the weight spectrum are unknown. Objective: To determine whether overnight serum OXT levels are (1) elevated in OB and (2) associated with body composition, BMD, and hip geometry across the weight spectrum. Design: Cross-sectional. Setting: Clinical research center. Participants: Fifty-nine women, ages 18 to 45 years: amenorrheic AN (N = 16), eumenorrheic HC (N = 24), eumenorrheic OB (N = 19). Main Outcome Measures: Serum sampled every 20 minutes from 8 pm to 8 am and pooled for integrated overnight OXT levels. Body composition, BMD, and hip structural analysis measured by dual x-ray absorptiometry. Results:OXT levels were lowest in AN, higher in HC, and highest in OB (P ≤ 0.02). There were positive associations between OXT and (1) body mass index (P = 0.0004); (2) total, visceral, and subcutaneous fat (P ≤ 0.0002); (3) spine and hip BMD Z-scores (P ≤ 0.01); and (4) favorable hip geometry, namely buckling ratio (P ≤ 0.05). In a subset analysis of HC and OB, relationships between OXT and body composition, but not bone parameters, remained significant. Conclusions: These data suggest OXT is a marker of energy availability and may be a mediator of bone density, structure, and strength. OXT pathways may provide targets for obesity and osteoporosis treatment.
Authors: Melanie Schorr; Elizabeth A Lawson; Laura E Dichtel; Anne Klibanski; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Elizabeth A Lawson; Daniel Donoho; Karen K Miller; Madhusmita Misra; Erinne Meenaghan; Janet Lydecker; Tamara Wexler; David B Herzog; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2009-10-16 Impact factor: 5.958
Authors: Sven Prevrhal; John A Shepherd; Kenneth G Faulkner; Ken W Gaither; Dennis M Black; Thomas F Lang Journal: J Clin Densitom Date: 2008-02-15 Impact factor: 2.617
Authors: Roberto Tamma; Graziana Colaianni; Ling-ling Zhu; Adriana DiBenedetto; Giovanni Greco; Gabriella Montemurro; Nicola Patano; Maurizio Strippoli; Rosaria Vergari; Lucia Mancini; Silvia Colucci; Maria Grano; Roberta Faccio; Xuan Liu; Jianhua Li; Sabah Usmani; Marilyn Bachar; Itai Bab; Katsuhiko Nishimori; Larry J Young; Christoph Buettner; Jameel Iqbal; Li Sun; Mone Zaidi; Alberta Zallone Journal: Proc Natl Acad Sci U S A Date: 2009-04-15 Impact factor: 11.205
Authors: Elizabeth A Lawson; Dean A Marengi; Rebecca L DeSanti; Tara M Holmes; David A Schoenfeld; Christiane J Tolley Journal: Obesity (Silver Spring) Date: 2015-04-10 Impact factor: 5.002
Authors: Robyn P Thom; Christopher J Keary; Michelle L Palumbo; Caitlin T Ravichandran; Jennifer E Mullett; Eric P Hazen; Ann M Neumeyer; Christopher J McDougle Journal: Psychopharmacology (Berl) Date: 2019-05-28 Impact factor: 4.530
Authors: Anna Aulinas; Francisco J Guarda; Elaine W Yu; Melanie S Haines; Elisa Asanza; Lisseth Silva; Nicholas A Tritos; Joseph Verbalis; Karen K Miller; Elizabeth A Lawson Journal: Neuroendocrinology Date: 2020-02-20 Impact factor: 4.914
Authors: Mone Zaidi; Maria I New; Harry C Blair; Alberta Zallone; Ramkumarie Baliram; Terry F Davies; Christopher Cardozo; James Iqbal; Li Sun; Clifford J Rosen; Tony Yuen Journal: J Endocrinol Date: 2018-03-19 Impact factor: 4.286